Calyx Announces Commercial Launch of Higher Yielding Variety of Resonance(R) Carinata


VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 15, 2013) - Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is pleased to announce the commercial launch of an improved variety of Resonance® carinata, an industrial oilseed crop that is proprietary to Calyx's operating subsidiary, Agrisoma Biosciences Inc. Oil extracted from carinata can be refined into fuels used as 100 percent petroleum substitutes.

Performance trials of this next-generation variety of Resonance carinata, AAC A110, delivered an average yield improvement of 7% compared to the existing Resonance carinata variety, AAC A100 (where yield is measured as the weight of the crop harvested per acre). AAC A110 also demonstrated an improved meal profile. The AAC A110 variety was developed and extensively field-tested over the last three growing seasons at multiple locations in Western Canada.

"The yield improvements from AAC A110 enables production of more oil for every acre planted, compared to the AAC A100 line. This further substantiates the value proposition for Resonance carinata to become the leading oilseed crop for the biofuel industry," said Hugh Notman, CEO of Calyx. "Continuing to develop higher yielding varieties is a high priority for our company."

Performance trials of AAC A110 resulted in yields as high as 44 bushels per acre. AAC A110 also resulted in an improved meal (the resulting byproduct of carinata after the oil has been extracted) profile. Resonance carinata produces a high-soluble protein meal that can be sold into the cattle feed market.

AAC A110 has the same seeding rates and crop inputs (fertilizer, weed and insect control) as A100, and costs the same to produce, treat, clean and deliver to farmers.

"Ultimately we get a better crop that results in even better land utilization, which has implications across the entire value chain," Notman said. "Equally important is that the production and use of carinata as a fuel substantially reduces carbon and other harmful emissions."

Beginning with the current planting season, AAC A110 will be the variety of Resonance carinata sold for commercial production.

About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company focused on renewable fuels including biojet and biodiesel. Calyx's majority-owned operating subsidiary, Agrisoma Biosciences Inc., is producing a new proprietary non-food energy feedstock crop, Resonance® carinata, which yields oil that can be refined into fuels that work in existing engines as a 100 percent petroleum substitute. From seed to sky, fuels produced from Resonance® carinata substantially reduce carbon and other harmful emissions, and help to reduce global petroleum dependence. For further information about Calyx, please visit www.calyxbio.com. Resonance® is a registered trademark of Agrisoma Biosciences Inc.

Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx and/or Agrisoma, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, results of operations or performance that may constitute "forward-looking statements" or "forward-looking information" under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx's and/or Agrisoma's control, including general business, economic, competitive, political and social uncertainties; the delay or failure to receive regulatory approvals, the characteristics and viability for bio-fuel development, the willingness of third parties to conclude agreements with Calyx and/or Agrisoma on terms that are acceptable to management of Calyx and/or Agrisoma, and the ability of Calyx and/or Agrisoma to secure sufficient future funding to carry out all of its business plans.

Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect. In addition to other assumptions identified in this news release, assumptions have been made regarding, among other things, commodity prices, operating conditions, capital and other expenditures, and project development activities.

Although Calyx and/or Agrisoma believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx and/or Agrisoma can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and/or Agrisoma and described in the forward-looking statements or information.

The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx and/or Agrisoma undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy, any securities in the United States, nor shall there be any sale of securities mentioned in this press release in any state in the United States in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Calyx Bio-Ventures Inc.
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com

Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com